Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (3)

ProteinN (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 3 records in total 3
    records per page




    Evaluation of vertical transmission of SARS-CoV-2 in utero: nine pregnant women and their newborns

    Authors: Liang Dong; Shiyao Pei; Qin Ren; Shuxiang Fu; Liang Yu; Hui Chen; Xiang Chen; Mingzhu Yin

    doi:10.1101/2020.12.28.20248874 Date: 2021-01-08 Source: medRxiv

    BackgroundSevere acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), mainly transmitted by droplets and close contact, has caused a pandemic worldwide as of November 2020. According to the current case reports and cohort studies, the symptoms of pregnant women infected with SARS-CoV-2 were similar to normal adults and may cause a series of adverse consequences of pregnancy (placental abruption, fetal distress, epilepsy MESHD during pregnancy, etc.). However, whether SARS-CoV-2 can be transmitted to the fetus through the placental barrier is still a focus of debate. MethodsIn this study, in order to find out whether SARS-CoV-2 infect MESHD fetus through placental barrier, we performed qualitative detection of virus structural protein (spike PROTEIN protein and nucleoprotein PROTEIN) and targeted receptor protein ( ACE2 HGNC, CD147 HGNC and GRP78 HGNC) expression on the placental tissue of seven pregnant women diagnosed with COVID-19 MESHD through immunohistochemistry. Amniotic fluid, neonatal throat, anal swab and breastmilk samples were collected immediately in the operating room for verification after delivery, which were all tested for SARS-CoV-2 by reverse transcriptionpolymerase chain reaction (RT-PCR). Results: The result showed that CD147 HGNC was expressed on the basal side of the chorionic trophoblast cell membrane and ACE2 HGNC was expressed on the maternal side, while GRP78 HGNC was strongly expressed in the cell membrane and cytoplasm. The RT-PCR results of Amniotic fluid, neonatal throat, anal swab and breastmilk samples were all negative. Conclusions: We believed that despite the detection of viral structural proteins in the placenta, SARS-CoV-2 cannot be transmitted to infants due to the presence of the placental barrier.

    The SARS-CoV-2 spike PROTEIN protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 HGNC receptor-mediated signalling: a potential non-infective mechanism of COVID-19 MESHD microvascular disease

    Authors: Elisa Avolio; Monica Gamez; Kapil Gupta; Rebecca Foster; Imre Berger; Massimo Caputo; Andrew D. Davidson; Darryl Hill; Paolo Madeddu; Shawn A Abbasi; Whitney Pickens; Katia George; Daniel R Boutz; Dalton M Towers; Jonathan R McDaniel; Daniel Billick; Jule Goike; Lori Rowe; Dhwani Batra; Jan Pohl; Justin Lee; Shivaprakash Gangappa; Suryaprakash Sambhara; Michelle Gadush; Nianshuang Wang; Maria D Person; Brent L Iverson; Jimmy D Gollihar; John Dye; Andrew Herbert; Ralph S Baric; Jason S McLellan; George Georgiou; Jason J Lavinder; Gregory C Ippolito; Fergus Gleeson; Yper Hall; Simon G. P. Funnell; Sally Sharpe; Francisco Javier Salguero; Andrew R Gorringe; Miles Carroll

    doi:10.1101/2020.12.21.423721 Date: 2020-12-21 Source: bioRxiv

    Background: Severe coronavirus disease 2019 MESHD ( COVID-19 MESHD) manifests as a life-threatening microvascular syndrome MESHD. The severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) uses primarily the capsid spike (S) protein PROTEIN to engage with its receptors and infect host cells. To date, it is still not known if the S protein PROTEIN alone, without the other viral elements, is able to trigger vascular cell signalling and provoke cell dysfunction. Methods: We investigated the effects of the recombinant, stabilised S protein PROTEIN on primary human cardiac pericytes (PCs) signalling and function. Endpoints included cell viability, proliferation, migration, cooperation with endothelial cells (ECs) in angiogenesis assays, and release of pro-inflammatory cytokines. Adopting a blocking strategy against the S protein PROTEIN receptors ACE2 HGNC and CD147 HGNC, we explored which receptor mediates the S protein PROTEIN signalling in PCs. Findings: We show, for the first time, that the recombinant S protein PROTEIN alone elicits functional alterations in cardiac PCs. This was documented as: (1) increased migration, (2) reduced ability to support EC network formation on Matrigel, (3) secretion of pro-inflammatory molecules typically involved in the cytokine storm; and (4) production of pro-apoptotic factors responsible for EC death MESHD. Furthermore, the S protein PROTEIN stimulates the phosphorylation/activation of the extracellular signal-regulated kinase 1/2 HGNC (ERK1/2) through the CD147 HGNC receptor, but not ACE2 HGNC, in cardiac PCs MESHD. Accordingly, the neutralization of CD147 HGNC, using a blocking antibody, prevented the activation of ERK1/2 and partially rescued the PC function in the presence of the S protein PROTEIN. Interpretation: Our findings suggest the new, intriguing hypothesis that the S protein PROTEIN may elicit vascular cell dysfunction MESHD, potentially amplifying, or perpetuating, the damage caused by the whole coronavirus. This mechanism may have clinical and therapeutic implication.

    Meplazumab treats COVID-19 MESHD pneumonia: an open-labelled, concurrent controlled add-on clinical trial

    Authors: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu

    doi:10.1101/2020.03.21.20040691 Date: 2020-03-24 Source: medRxiv

    Background: SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 HGNC could bind spike protein PROTEIN of SARS-CoV-2 and involve in host cell invasion. Antibody against CD147 HGNC could block the infection of SARS-CoV-2 MESHD. We aimed to assess the efficacy and safety of meplazumab, a humanized anti- CD147 HGNC antibody, as add-on therapy in patients with COVID-19 MESHD pneumonia MESHD. Methods: All patients received recommended strategy from Diagnosis and Treatment for 2019 Novel Coronavirus Disease MESHD Coronavirus Diseases MESHD released by National Health Commission of China. Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5. Patients hospitalized in the same period were observed as concurrent control. The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test. This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245. Findings:17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia MESHD with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 MESHD pneumonia MESHD. Funding:National Science and Technology Major Project.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.